CTD Hikes on Niemann-Pick Treatment Trials
AllpennyStocks.com

CTD Hikes on Niemann-Pick Treatment Trials

By: Dylan Sikes – AllPennyStocks.com News

Thursday, May 23, 2019

New developments were publicized Thursday in the effort to save lives, as Florida-based CTD Holdings Inc (OTC:CTDH) announced its first home-based infusion of its proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo, in a formal clinical trial.

Thursday’s news release said the trial is focusing on the long-term safety of Intravenous Trappsol® Cyclo in patients with Niemann-Pick Disease Type C (NPC-1) in the United States.

CEO Scott Fine says, "Today's infusion is a milestone for all who have supported CTD's clinical program from the very beginning. We are pleased to be able to provide home-based infusions to NPC patients even as we continue to gather data needed to support market registration of Trappsol® Cyclo for NPC."

CTD claims to be, again, quoting the release, “a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need.” 

While the volume wasn’t there by noon Thursday – only 10,000 shares – price action certainly turned heads, climbing 14 cents, or 20%, to 83.9 cents. 

 

 


Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon

Other Penny Stock Movers

Shares of Dual-Listed Miner Up on News of Options on Uranium Properties
 Read More
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
 Read More
Could This Stock Be The Next Big Mover In The Short-Term Rental Market?
 Read More
Most Popular
1
Micro Cap Massively Bid Up Before Opening Bell
2
Could This Stock Be The Next Big Mover In The Short-Term Rental Market?
3
Dual Listed Biotech Firm Achieves Sale of Animal Health Interest, Sending Shares Higher
4
Dr. Martens shares lose a third of their value on U.S. warning
5
Gold to ‘shine bright like a diamond,’ hit $3,000 within months, says Citigroup
6
Shares of Dual-Listed Gold Miner Bid Up After Earnings Release
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top
Site Links:
Premium Services / Email Newsletter:
Social Media:
RSS Feed:
Partners:
© Copyright 2024 AllPennyStocks.com Media Inc. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes.
Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Data is provided by QuoteMedia.com.
© Copyright 1999 – 2024. AllPennyStocks.com Media Inc.
All rights reserved.